-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Measurable Residual Disease Testing in AML: Challenges and Progress

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
Hematology Disease Topics & Pathways:
Clinical trials, Research, Clinical Practice (Health Services and Quality), Clinical Research, Measurable Residual Disease
Monday, December 9, 2024, 10:30 AM-12:00 PM

Christopher S. Hourigan, DM DPhil

Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC

Disclosures: Hourigan: Illumina: Other: Research Collaboration .

See more of: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>